Insulin Family intermediate
Insulin Injection Site Lipohypertrophy
Lipodystrophy at insulin injection sites caused by localized anabolic effects leading to erratic absorption. This peptide or oligopeptide is studied for its ...
By Encyclopeptide Editorial | 1 min read
insulin lipohypertrophy injection-site complication diabetes
Overview
Lipohypertrophy is the most common injection-related complication of insulin therapy, occurring in 30-60% of patients due to local anabolic effects on subcutaneous adipose tissue.
Clinical Consequences
- Erratic insulin absorption (25-50% variability)
- Unexplained glycemic variability
- Increased insulin requirements
- Poor glycemic control despite appropriate dosing
Prevention and Management
- Systematic site rotation at every injection
- Regular palpation of injection sites
- Education on proper injection technique
Chemical Identity
| Property | Value |
|---|---|
| Name | Insulin Injection Site Lipohypertrophy |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Insulin Injection Site Lipohypertrophy” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Injection Site Lipohypertrophy with interactive quizzes on Wikipept.
Take a Quiz on Wikipept